A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects
Not Applicable
Completed
- Conditions
- Healthy
- Registration Number
- NCT04603378
- Lead Sponsor
- Kaleido Biosciences
- Brief Summary
This exploratory, randomized, double-blind, placebo-controlled study aims to explore the effect of novel glycans on nitrogen metabolism in the gut in healthy subjects using a stable isotope.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of patients experiencing any treatment-emergent adverse events (TEAEs) Day -8 to Day 29
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms do novel glycans influence in gut nitrogen metabolism according to NCT04603378?
How do novel glycans compare to prebiotics in modulating intestinal nitrogen homeostasis in healthy individuals?
What biomarkers correlate with changes in gut nitrogen metabolism following glycan administration in NCT04603378?
What adverse events are associated with novel glycans in gut microbiome modulation studies?
What other compounds or therapies are being studied for gut nitrogen metabolism by Kaleido Biosciences?
Trial Locations
- Locations (1)
PPD Phase I Clinic
🇺🇸Austin, Texas, United States
PPD Phase I Clinic🇺🇸Austin, Texas, United States